

NEWSLETTER
CHEMICAL & PHARMACEUTICAL
20 - 26 October 2025



Mexico Issues Preliminary Anti-Dumping Ruling on Chinese Polycarbonate Sheets

On October 7, 2025, the Mexican Ministry of Economy issued a notice issuing a preliminary affirmative anti-dumping ruling on finished and semi-finished polycarbonate sheets originating in China, preliminarily imposing provisional anti-dumping duties on the products involved. The measures will take effect from the day after the announcement and will remain in effect for four months. **(China Trade Remedy Information Network)**

Australia Issues Final Ruling on Chinese Aluminum Extrusions

The Australian Anti-Dumping Commission issued Announcement No. 2025/096, stating that Australia approved the final ruling of the third sunset review of anti-dumping and countervailing duties on aluminum extrusions imported from China. Australia decided to continue to implement anti-dumping and countervailing duties on the products involved from China, effective October 29, 2025, at rates ranging from 0.8% to 29.4%. **(China Trade Remedy Information Network)**

Measures announced to encourage development of innovative drugs

China's healthcare authorities have introduced new measures to boost innovative drug development, including a dedicated commercial insurance catalog for high-value drugs not covered by basic medical insurance. This initiative aims to expand coverage through commercial health insurance, medical aid, and other plans, addressing gaps in basic insurance which already covers 1.326 billion people. **(China Daily)**

TCM footprint now covers 196 countries; acupuncture recognized by 113 WHO members

TCM (Traditional Chinese medicine) has spread to 196 countries and nations across the world and more than 100 types of TCM drugs have obtained registration in countries involved in the Belt and Road Initiative, with the market size estimated to exceed 4.8 trillion yuan (569.6 billion euro) by 2025. Acupuncture is now recognized in 113 member states of the World Health Organization. **(National Health Commission)**

China's first 9-valent HPV vaccine priced at just 60 euro

China's first domestically developed 9-valent HPV vaccine has been priced at 499 yuan (60 euro) per dose, offering people a new choice for HPV vaccination. Following 18 years of effort, the domestically developed 9-valent HPV vaccine has demonstrated trial data comparable to that of imported ones. To date, 70 to 80% of China's 300 million females aged 9 to 45 remain unvaccinated against HPV. **(China Daily)**